September 22, 2020

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Intimation of Investor/ Analyst Meetings on September 22, 2020

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company is organising a Conference Call with the Investor/analysts on September 22, 2020. We enclose details of analyst conference calls scheduled for the same.

We also enclose the presentation to be used during the Conference Call.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

RAJIV SHAH
Rajiv Shah
Company Secretary

Encl.: as above
**Investor/ Analyst Conference Call details**

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baring Asset Management - United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Banque Pictet &amp; Cie Sa</td>
<td></td>
</tr>
<tr>
<td>UBS Wealth Management - HK</td>
<td></td>
</tr>
<tr>
<td>Franklin Advisors - United States</td>
<td></td>
</tr>
<tr>
<td>Banco Finantia</td>
<td></td>
</tr>
<tr>
<td>Hong Kong Asset Management Limited</td>
<td></td>
</tr>
<tr>
<td>HSBC Global Asset Management (Hong Kong) Limited</td>
<td></td>
</tr>
<tr>
<td>Julius Baer &amp; Co, Ltd - Switzerland</td>
<td></td>
</tr>
<tr>
<td>J.P. Morgan</td>
<td></td>
</tr>
<tr>
<td>Eastspring Investments - Singapore</td>
<td></td>
</tr>
<tr>
<td>Loomis Sayles &amp; Company - Singapore</td>
<td></td>
</tr>
<tr>
<td>Vontobel Asset Management AG</td>
<td></td>
</tr>
<tr>
<td>Aminvestment Group Berhad</td>
<td></td>
</tr>
<tr>
<td>Bea Union Investment Management Limited - Hong Kong</td>
<td></td>
</tr>
<tr>
<td>BNP Paribas Asset Management Asia Limited</td>
<td></td>
</tr>
<tr>
<td>Pictet Asset Management Limited</td>
<td></td>
</tr>
<tr>
<td>Aegon Americas - United States</td>
<td></td>
</tr>
<tr>
<td>Arkkan Capital Management Limited</td>
<td></td>
</tr>
<tr>
<td>LGT Capital Partners</td>
<td></td>
</tr>
<tr>
<td>GIC Private Limited</td>
<td></td>
</tr>
<tr>
<td>Pharo Management (HK) Limited - Hong Kong</td>
<td></td>
</tr>
</tbody>
</table>
This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Pharma Limited (the “Company” or “JPL”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for use by the recipient only. The Presentation shall not, in whole or in part, be disclosed without prior written consent of the Company. This Presentation must not be copied, reproduced, distributed, or otherwise disclosed or passed on to others, in whole or in part, by any means, in any form under any circumstances whatsoever at any time hereafter. In furnishing this document, neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, undertake any obligation to provide to the recipient (a) access to any additional information or to update this document, or (b) to correct any inaccuracies therein which may or may not become apparent.

This Presentation may contain statements about events and expectations that may be “forward-looking”, including statements relating to future status, events, prospects or circumstances, including but not limited to statements about plans and objectives, outlook, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such forward looking statements are made based on management’s current expectations or beliefs as well as assumptions made (in good faith) by, and information currently available to, the management. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from these forward-looking statements due to number of risks and uncertainties, including future changes or developments in the Company’s business, its competitive environment, its ability to implement its strategies and initiatives, respond to industry changes and the political, economic, regulatory and social conditions in India. The Company may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

This Presentation does not constitute a prospectus, offering circular or offering memorandum or an offer or invitation or a solicitation of any offer to purchase or sell, any securities of the Company, and should not be considered or construed in any manner whatsoever as a recommendation that any person should subscribe for or purchase any of Company’s securities. None of the projections, expectations, estimates or prospects in this Presentation should be construed as a forecast implying any indicative assurance or guarantee of future performance, nor that the assumptions on which such future projections, expectations, estimates, or prospects have been prepared are complete or comprehensive.

This Presentation utilizes information which has not been independently verified (including by opinion, anecdote and speculation) and which has been sourced from a variety of public sources and third parties. Neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, makes any representation or warranty (expressly or impliedly) as to the accuracy, adequacy or completeness of this document or its contents or of any other oral or written information furnished or made available. The Company disclaims to the extent possible by law, all responsibility in relation to this Presentation.

This Presentation, is not a recommendation to invest, is not an investment advice, and, is prepared to provide background information for investors in relation to the Company. This Presentation does not purport to contain all information investors may require to evaluate an investment in the Company. In preparing the Presentation, the Company have not taken into account the particular investment objectives, financial situation or particular needs of investors. Before making an investment decision, an investor should independently consider whether an investment in the Company is appropriate in light of its particular investment needs, objectives and financial circumstances. An investor should conduct its own independent investigations, due diligence and analysis of the potential benefits and risks of any investment in the Company. An investor should seek professional advice, including tax advice before making an investment decision.

This Presentation contains certain non-IFRS measures, including EBITDA and EBITDA margin. The measures have been used by management as supplemental measures of the Company’s performance and are not required by, or presented in accordance with, IFRS. Further, these non-IFRS measures are not measures of financial performance or liquidity under IFRS and should not be considered alternatives to result from operating activities, profit before tax, profit for the year or any other performance measure derived in accordance with IFRS or as an alternative to cash flow from operating activities. You should not consider these non-IFRS measures in isolation from, or as a substitute for, analysis of the financial condition or results of operations of the Group, as reported under IFRS.

This Presentation also contains certain statistical data and analyses (the "Statistical Information") which have been prepared in reliance upon information furnished by the Company and/or third party sources for which the Company has either obtained or is in the process of obtaining the necessary consents for use. Numerous assumptions were used in preparing the Statistical Information, which assumptions may or may not appear herein. As such, no assurance can be given as to the Statistical Information’s accuracy, appropriateness or completeness in any particular context, nor as to whether the Statistical Information and/or the assumptions upon which they are based reflect present market conditions or future market performance. Moreover, any information from third party sources contained in these materials may not be used or relied upon by any other party, or for any other purpose, and may not, directly or indirectly, be reproduced, disseminated or quoted without the prior written consent of such third party.

This Presentation does not constitute or form a part of any offer to sell, offer to purchase, or a solicitation to sell or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction. No securities of or relating to the Company referred to herein have been, and will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state of the United States or any other jurisdiction and no such securities may be offered or sold in the United States absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and the rules and regulations thereunder. No public offering of securities will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. Any offer of such securities will be made by means of an offering document that will contain detailed information about the Company and its subsidiaries, the securities, as well as the Company’s financial statements.

This Presentation may not be taken or transmitted into the United States, Canada or Japan and are not for distribution, directly or indirectly, in or into the United States, Canada or Japan. The distribution of this Presentation in or from certain other jurisdictions may also be restricted or prohibited by law. Recipients are required to inform the Company of, and comply with, all restrictions or prohibitions in relevant jurisdictions. Neither the Company nor any other person shall have any liability to any person in relation to the distribution or possession of this document or copies thereof in or from any jurisdiction where the distribution of such a document is prohibited or requires special authorization or any regulatory consent or approval. By accepting this document the recipient has agreed, upon request, to return promptly all material received from the Company without retaining any copies.

By accepting this Presentation, the recipient agrees that this Presentation, and any other oral or written information made available in relation the Company, is strictly confidential and shall not be copied, published, distributed or transmitted to any person, in whole or in part, by any means, in any form under any circumstances whatsoever and that the recipient has further agreed, upon request, to return promptly all material received from the Company without retaining any copies. The recipient further represents and warrants that it is lawfully able to receive this Presentation under the laws of the jurisdiction in which it is located and / or any other applicable laws, and that it will not reproduce, publish, disclose, distribute or transmit this Presentation.
Jubilant Pharma Limited

- Key Highlights
- Appendix
Jubilant Pharma – A Global Integrated Pharmaceuticals Company

Business Segments

- Specialty Pharmaceuticals
  - Jubilant Pharma Limited (Singapore) (JPL)
  - Radiopharma
    - 53.1%
  - Allergy Therapy Products (ATPs)
    - 45.9%
  - 7.2%

- CDMO
  - 27%
  - Contract Manufacturing of Sterile Injectables & Non Sterile Products (CMO)
  - 15.8%
  - Active Pharma Ingredients (APIs)
  - 11.2%

- Generics
  - 19.9%
  - Solid Dosage Formulations (SDFs)

Financial Highlights

<table>
<thead>
<tr>
<th>(US$m, unless stated)</th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
<th>CAGR FY18-20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue from operations</td>
<td>619</td>
<td>761</td>
<td>803</td>
<td>14%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>151</td>
<td>192</td>
<td>211</td>
<td>18%</td>
</tr>
<tr>
<td>EBITDA margin(1)</td>
<td>24.5%</td>
<td>25.2%</td>
<td>26.2%</td>
<td></td>
</tr>
<tr>
<td>PAT</td>
<td>49</td>
<td>59</td>
<td>92</td>
<td>37%</td>
</tr>
<tr>
<td>PAT margin(1)</td>
<td>7.9%</td>
<td>7.7%</td>
<td>11.4%</td>
<td></td>
</tr>
</tbody>
</table>

Key Business Highlights

- 80%+ revenues from North America
- 6 Manufacturing facilities in the US, Canada and India
- Strong R&D capabilities
- Over 80 countries served
- Long-standing customer relationships
- c.43% supplies from top 10 suppliers
- Highly qualified and dedicated Board; Experienced management team
- c.31% revenues derived from top 10 customers(2)
- c.42% revenues derived from top 10 products
- c.5,200 employees worldwide(3)

(1) Calculated as % of revenue from operations
(2) Excluding GPOs but including customers purchasing goods and services through such GPOs
(3) As of March 31, 2020

Jubilant Pharma – A Global Integrated Pharmaceuticals Company

Jubilant Pharma Limited (Singapore) (JPL)

Radiopharma

- Contract Manufacturing of Sterile Injectables & Non Sterile Products (CMO)
- 15.8%

Allergy Therapy Products (ATPs)

- Active Pharma Ingredients (APIs)
- 11.2%

Generics

- Solid Dosage Formulations (SDFs)
- 19.9%

% of FY20 Revenue

(US$m, unless stated) FY18 FY19 FY20 CAGR FY18-20
Revenue from operations 619 761 803 14%
EBITDA 151 192 211 18%
EBITDA margin(1) 24.5% 25.2% 26.2% 
PAT 49 59 92 37%
PAT margin(1) 7.9% 7.7% 11.4%

Key Business Highlights

- 80%+ revenues from North America
- 6 Manufacturing facilities in the US, Canada and India
- Strong R&D capabilities
- Over 80 countries served
- Long-standing customer relationships
- c.43% supplies from top 10 suppliers
- Highly qualified and dedicated Board; Experienced management team
- c.31% revenues derived from top 10 customers(2)
- c.42% revenues derived from top 10 products
- c.5,200 employees worldwide(3)

(1) Calculated as % of revenue from operations
(2) Excluding GPOs but including customers purchasing goods and services through such GPOs
(3) As of March 31, 2020
Evolution of Jubilant Pharma

**Successful acquisition track record, accompanied by strong revenue and profitability growth**

- **FY20**: US$803m (Growth: 6%)
- **FY19**: US$761m

### Revenue Contribution
- Specialty Pharmaceuticals: 53.2%
- Generics: 46.4%
- CDMO: 10.5%

- **FY20**
  - Specialty Pharmaceuticals: 53.1%
  - Generics: 19.3%
  - CDMO: 27%

- **FY19**
  - Specialty Pharmaceuticals: 53.2%
  - Generics: 45.9%
  - CDMO: 14.7%

**Continued Focus on Specialty Pharmaceuticals – Radiopharmaceuticals, Contract Manufacturing and Allergy Therapy Products**

**JLL acquired API business – Nanjangud, Karnataka, India**

**Acquired a majority stake in Cadista Holdings Inc. (generics pharmaceutical company in the US) with a USFDA approved manufacturing facility for solid dosage formulations**

**Acquired Draxis Pharma Inc. in Canada (manufacturer of sterile products, non-sterile products and radiopharmaceuticals)**

**SGX-listed high yield bond offering – USD 300 million**

**Completed acquisition of Triad’s radiopharmacies in the US**

**FY03**
- Acquired Pharmaceutical Services Incorporated N.V. and PSI Supply N.V. (Belgium)

**FY04**
- Created R&D centre for solid dosage formulations

**FY05**
- Acquired HollisterStier Laboratories LLC in US (a CMO service provider)

**FY06**
- Fund raising from IFC through a mix of debt and convertible instruments

**FY07**
- Acquired balance of minority stake in Cadista Holdings Inc.

**FY08**
- Consolidation of the pharmaceutical business under JPL

**FY09**
- SGX-listed high yield bond offering – USD 200 million

**FY10**
- JLL acquired API business – Nanjangud, Karnataka, India

**FY11**
- Acquired a majority stake in Cadista Holdings Inc.

**FY12**
- Created R&D centre for solid dosage formulations

**FY13**
- Acquired Draxis Pharma Inc. in Canada

**FY14**
- SGX-listed high yield bond offering – USD 300 million

**FY15**
- Completed acquisition of Triad’s radiopharmacies in the US

**FY16**
- JLL acquired API business – Nanjangud, Karnataka, India

**FY17**
- Acquired a majority stake in Cadista Holdings Inc.

**FY18**
- Created R&D centre for solid dosage formulations

**FY19**
- Acquired Draxis Pharma Inc. in Canada

**FY20**
- SGX-listed high yield bond offering – USD 300 million
Radiopharmaceuticals Business

Industry Overview
- Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach US$3.5bn by 2023.
- Oncology and cardiology diagnosis accounted for 69.4% of the industry in 2017.
- Increase of cardiovascular, cancerous and neurological diseases are likely to drive molecular imaging procedures.

Business Overview
- Specializes in cardiology, pulmonology, oncology and endocrinology as well as bone, brain and renal imaging.
- Supplies 14 diagnostic and therapeutic radiopharmaceutical products to 18 countries.
- #3 radiopharmaceutical manufacturer in nuclear medicine industry for the US based on revenue.(1)
- Customers include 3rd party commercial radiopharmacy networks, our radiopharmacies, hospitals, standalone imaging centers and cardiologists.
- Long-term contracts in place in the US.
- USFDA approved manufacturing facility at Kirkland, Montreal.

Products
- DRAXIMAGE® MAA for lung perfusion imaging (dominant supplier in the US for MAA).
- DRAXIMAGE® DTPA for lung ventilation and renal imaging (sole supplier in the US).
- HICON® Sodium Iodine-131 solution for thyroid disease and thyroid cancer management (HICON® Sodium Iodine-131 solution for thyroid disease and thyroid cancer management (We are one of three USFDA approved manufacturers globally).
- Drax Exametazime TM (505(b)(2)product) for intra-abdominal infection and inflammatory bowel disease.
- RUBY-FILL® Rubidium Rb82 Generator and Elution SystemTM (505(b)(2)products) for myocardial perfusion imaging with PET.
- Planning to file NDA for l-131 mIBG (currently undergoing Phase II and Phase III clinical trials in the US) and 505(b)(2) for 7 other products.
- Entered into a MoU for Technetium 99 Tilmanocept (entering into Phase 3 clinical trials for RA) with Navidea Biopharmaceuticals Inc.
- Signed an agreement for the exclusive distribution of Eckert & Ziegler’s proprietary generator “GalliaPharm®” (neuroendocrine cancers) in Canada.

Strategy
- Achieve market leadership in the nuclear medicine industry.
- Increase market share of RUBY-FILL® Rubidium Generator and Elution SystemTM - cardiac PET imaging. Planning to launch Ruby-Fill in Europe in FY21.
- Leverage leadership in existing products.
- Expand product portfolio through launch of niche and differentiated products.

Radiopharmaceuticals Business – Key products

- **RUBY-FILL® (Rubidium Rb 82 Generator) and Elution System**
- **Kit for the Preparation of Technetium Tc 99m Albumin Aggregated Injection (MAA)**
- **HICON® Sodium Iodide I 131 Solution USP**
Radiopharmacy Business

- #2 commercial radiopharmacy network\(^{(1)}\) in the US, operated under the Jubilant Radiopharmacy brand
  - Facilities include three operational cyclotrons
- Multi-year agreements with GPOs in place

Strategy

Build the nation’s premier radiopharmacy network

- Optimizing coverage of radiopharmacy network through further additions and improvements or consolidation
- Upgradation of a few sites in progress. Efforts also underway to improve operational efficiencies
- Establish new distribution channels through collaboration and contractual arrangements with strategic partners
- Geographic expansion in US and Canada by increasing brand recognition among hospital networks

- Over 50 radiopharmacies spread across 22 states
- ~750 employees
- c.3m+ doses delivered annually
- c.1,700 customers across national GPOs, regional Networks, local hospitals and physician groups
- Strong relationships with major national GPOs

Allergy Therapy Business

Industry Overview
- Global AIT market stands at US$1.7bn and is expected to grow at CAGR of 8.9% to reach US$2.8bn by 2022.
- Major growth drivers include the increased prevalence of allergic diseases, reduced time to drug approval processes and increased pharmaceutical R&D spending & biotechnology investment.
- Venom immunotherapy is considered effective for the prevention of potential allergic reactions to hymenoptera stings.
- Jubilant HollisterStier is the sole supplier for venom immunotherapy in the US from FY19.

Business Overview
- Jubilant is the #2 player in the allergenic extract market in the US and the sole supplier for venom immunotherapy in the US.
- Offers a range of different allergenic extracts and standard allergy vaccine mixtures as well as insect venom products for the treatment of allergies to insect stings.
- Traditionally focused on North America as the key market, where significant brand loyalty is generated in respect of the “HollisterStier” brand.
- Dedicated sales force in the US and distributors in Europe, Canada and South Korea.
- Products are sold primarily in bulk and then mixed in the office/clinic environment.
- USFDA approved manufacturing facilities at Spokane, Washington facility.

Products
- Product range includes 200+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices.
- Currently the sole producer and supplier of venom products for the treatment of allergies in the US.
- Expect to benefit from barriers to entry as biotechnology products with grandfather status; new products require an NDA.

Strategy
- Leverage Existing Capabilities
  - Launch new, differentiated products and expand capacities in particular in venom and extract products.
  - Improve existing processes and supply reliability.
- Enhance US Footprint & Portfolio
  - Drive growth and profitability through our strong customer commitment to be partner-of-choice in the US allergy market.
- Expand Target Markets & Portfolio
  - Explore adjacencies or vertical integration such as supplier & distribution agreements or diagnostic testing services.
  - Entered into partnerships to further deepen market penetration in Canada and Europe.

Allergy Therapy Business – Key products

ComforTen Skin Test System

QUINTIP® Skin Test Device
CMO Business – Sterile Injectables and Non-Sterile Products

Industry Overview (Injectables) (1)
- Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a CAGR of 4.7% between 2017-23F to reach US$7.1bn.
- Growth drivers include consolidation in injectable CDMO space, shortage of injectable drugs, vendor consolidation and technical expertise for sterile injectable drugs.

Business Overview
- Sterile injectables account for c.80% while non-sterile products account for the balance c.20% of CMO revenues.
- Deep and long-term relationships with our top 10 customers - at least 10 years of business relationships with 6 of our top 10 customers.
- Fully integrated contract manufacturer of sterile injectables with in-house R&D capabilities – well positioned to become a leading, cost effective CMO.
- Full suite of services to our customers including supply chain support, lab testing services, regulatory submission support, manufacturing process refinement and project management.
- USFDA approved manufacturing facilities located in Spokane, Washington and Montreal, Canada.

Products
- **Sterile Injectables**
  - Freeze-dried (lyophilized) injectables, vial and ampoule liquid fills, biologics, water for injection diluents and sterile ointments, creams and liquids.
  - Currently produce vial ranges from 2 milliliters to 100 milliliters and batch sizes ranging up to 2,000 litres.
  - Capabilities to produce quantities for both large-scale commercial operations as well as for clinical trials.

- **Non-sterile Products**
  - Semi-solid dosage formulations, including antibiotic ointments, dermatological creams and liquids (syrups and suspensions).

Strategy
- **Enhance and expand capacity**
  - 30% Capacity Expansion through
    - Capacity addition by operating one line 24X7 effected in Spokane during Q3’FY19.
    - 24x7 shifts on another line from Q3’FY20.
    - New Lyo equipment capacity commercialised in Q1’FY21.

- **Achieve operational efficiencies**
  - Focus on First Time Right customer service and increase product filling yields.
  - Reduce time cycle between product releases.

- **Identify new customer targets**
  - New customer targets for ampoules, semi-solids and non-sterile liquids.
  - Focus on long term high value contracts.

- **Product portfolio extension**
  - Finding opportunities to strategically extend our product portfolio.
  - Evaluating opportunities for new product launches.

APIs Business

Industry Overview

- Global Synthetic API market is US$115bn in 2018 and is expected to grow at a CAGR of 6.7% from 2018 to 2022F to reach US$149bn\(^{(1)}\).
- 53% of outsourced API market is generics\(^{(1)}\).

Business Overview

- One of the global suppliers with market leadership in select key API products.
- c.80% of commercialized portfolio is in lifestyle driven therapeutic areas such as CVS and CNS, catering to an increasing incidence of lifestyle-related medical conditions or non-communicable diseases.
- c.60% of API sales are to regulated markets.
- Sartans continue to be a key focus area.
- API facility at Nanjangud, Karnataka (USFDA, Health Canada, PMDA Japan, KFDA Korea, COFEPRIS Mexico and Brazil ANVISA certifications).

Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Jubilant Global Market Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinaverium</td>
<td>61%</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>28%</td>
</tr>
<tr>
<td>Risperidone</td>
<td>24%</td>
</tr>
<tr>
<td>Meclizine</td>
<td>20%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Jubilant Global Market Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>18%</td>
</tr>
<tr>
<td>Donepezil</td>
<td>17%</td>
</tr>
<tr>
<td>Valsartan</td>
<td>8%</td>
</tr>
</tbody>
</table>

Strategy

- Continue to be a preferred supplier to our customers.
- Focus on product selection, new product launches and increasing market share of existing products.
- Well differentiated strategy of products and markets, focus on cost optimization supported by highly capable team with a proven track record to drive sustainable growth.
- Increasing the range of products in key markets such as US, Europe and expanding our geographical reach in select emerging markets.
- Continue to invest in R&D to build-up product pipeline and capacity expansion at plants.

---

Solid Dosage Formulations Business

Industry Overview

- Global generics pharmaceutical industry stands at US$106bn and is expected to grow at CAGR of 5.0% to reach US$136bn by 2022
- It is estimated that there will be c.US$73bn worth of small molecule drugs will have patent expiry from 2018-22
- Pharmerging market has seen strong growth both in volume (6.2%) and value (4.1%) in the recent past (2011-2016) driven by preference for branded generics coupled with increase in out-of-pocket spend

Business Overview

- 56 commercialized generic sound dosage formulations products across the US, Europe, Canada, Australia and the rest of the world
- 98 ANDA filings in the US - of which 35 are pending + 2 sterile injectables
- One of the market leaders in select key products in the US
- Benefit from backward integration into API business supported by in-house R&D facilities
- Manufacturing facility at Salisbury, US (USFDA) and Roorkee, India (PMDA Japan, ANVISA Brazil and MCC South Africa certifications)
- Expanded solid dosage formulations capacity at Roorkee facility now operational

Products

- #1 player in 4 products with over 45% share in each of the four products
- Amongst top 3 players in another 2 products
- Launched remdesivir in several countries including India in August 2020. Capacity of c. 200,000 vials to be doubled in 1.5-2 months

Strategy

- Aim is to be the first to enter and last to exit using our chemistry and R&D capabilities and manufacturing expertise to drive growth
- Focus on investment in R&D in order to increase our ANDA filings and approvals
- Focus on cost leadership with increased integration of in-house APIs
- Expand business into emerging markets by leveraging existing US filings

---


(2) As of March 31, 2020

(3) Only includes prescription drugs
High-Quality, World-Class Global Manufacturing Footprint

- Kirkland, Montreal, Canada
  - Contract Manufacturing of Sterile Injectables and non-sterile products
  - Radiopharmaceuticals
  - USFDA

- Spokane, Washington, USA
  - Contract Manufacturing of Sterile Injectables and Allergy Therapy Products
  - USFDA

- Salisbury, Maryland, USA
  - Solid dosage formulations
  - USFDA

- Yardley, Pennsylvania, USA
  - Corporate Office

- Nanjangud, Karnataka, India
  - API manufacturing
  - USFDA

- Roorkee, Uttarakhand, India
  - Solid dosage formulations
  - USFDA

- Noida, India
  - Dedicated R&D centres

- Singapore
  - Corporate Office

<table>
<thead>
<tr>
<th>Facility</th>
<th>USFDA Last inspection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montreal, CMO</td>
<td>May, 2018</td>
</tr>
<tr>
<td>Montreal, Radiopharma</td>
<td>Sep, 2017</td>
</tr>
<tr>
<td>Salisbury</td>
<td>Feb, 2020</td>
</tr>
<tr>
<td>Spokane</td>
<td>July, 2019</td>
</tr>
<tr>
<td>Roorkee</td>
<td>Nov, 2019</td>
</tr>
<tr>
<td>Nanjangud</td>
<td>Dec, 2018</td>
</tr>
</tbody>
</table>

4 manufacturing facilities in North America and 2 manufacturing facilities in India
Agenda

- Jubilant Group Overview
- Jubilant LifeSciences Overview
- Jubilant Pharma
  - Key Highlights
  - Appendix
Jubilant Pharma: Key Highlights

1. Leading Market Position Across Business Lines, with High Barriers to Entry for Specialty Pharmaceuticals

2. Diverse Sources of Revenue with a De-risked Business Model

3. Strong Product Pipeline with Deep R&D Capabilities

4. Global Competitive Edge due to Integrated and Efficient Manufacturing Operations

5. Demonstrated Financial Track Record with Strong Revenue Growth and Robust Balance Sheet

6. Strong Acquisitions and Integration Capabilities with a Proven Track Record

7. Highly Qualified, Experienced and Dedicated Board and Management Team
### Specialty Pharmaceuticals

#### Highlights
- #3 radiopharmaceuticals manufacturer in the US (1)
- #2 commercial radiopharmacy network in the US (1)
- Specialists in lung, thyroid, bone and cardiac imaging products
  - One of the two suppliers in the US for MAA; Sole supplier with 100% market share in the US for DTPA
  - One of three USFDA approved manufacturers globally of Iodine-131 (Thyroid)
  - Received two 505(b)(2) approvals for RUBYFILL® and DraxImage® Exametazime

#### Entry Barriers
- Extensive regulatory and licensing requirements
- Capital intensive nature of the business
- Vertical Integration with commercial radiopharmacy business

### Radiopharma

- # player in the allergenic extract market in the US
- Product range of 200+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices
- Sole producer and supplier of venom products in the US

### Allergy Therapy Products

- Biotechnology products with grandfather status; new products require an NDA
- Niche US allergen extract market

### CDMO

- Serves 7 out of the top 20 pharmaceutical companies globally based on revenue(1)
- Deep and long-term relationships with our top 10 customers
  - At least 10 years of business relationships with 6 of our top 10 customers

### CMO

- One of the market leaders in the US for several key API products
  - Pinaverium (global market share at c.61%)
  - Oxcarbazepine (global market share at c.28%)

### APIs

- Limited number of manufacturers with the requisite know-how for sterile injectables
- Proximity to customers
- Technical expertise required to develop products, obtain licensing and regulatory approvals

### Generics

- 56 commercial products across the, US, Europe, Canada, Australia and the rest of the world(2)
- #1 player in 4 products with over 45% share in each of the four products
- Amongst top 3 players in another 2 products
## Diverse Sources of Revenue with a De-risked Business Model

- **Jubilant Pharma’s de-risked business model benefits from its diversified product offerings, product sourcing capabilities as well as a broad customer base with a global manufacturing and distribution footprint.**

- **Presence across geographic locations enables Jubilant Pharma to capture different market segments.**

### Diverse Products

<table>
<thead>
<tr>
<th>FY20 Revenue Split</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diversified product portfolio</td>
</tr>
<tr>
<td>- Supplies 14 diagnostic &amp; therapeutic products in radiopharmaceuticals</td>
</tr>
<tr>
<td>- Over 200 allergy products</td>
</tr>
<tr>
<td>- 56 solid dosage formulations</td>
</tr>
<tr>
<td>- 44 commercialized APIs</td>
</tr>
</tbody>
</table>

### Broad Customer Base

- **Diversified customer base across five business lines**
- **Only one customer representing 5%+ contribution to total revenue**

### Geographic Diversification

- **Sales in over 80 countries**
- **Over 90% of sales in regulated markets such as North America and Europe - leading to sustainable revenues**

### Global Footprint

- **Global and diversified manufacturing footprint**
- **Locational advantage**
  - Closer to customers in North America
  - Distribution network of over 50 radiopharmacies across 22 states in the US

---

(1) As at March 31, 2020
(2) Excluding GPOs but including customers purchasing goods and services through such GPOs
Strong Product Pipeline with Deep R&D Capabilities

Strong R&D Capabilities...
- Capabilities demonstrated by specialized and niche product filings
- Dedicated team of 400+ R&D professionals
- R&D centers located in India and North America

...Resulting in Strong Product Pipeline

<table>
<thead>
<tr>
<th>Patents Granted</th>
<th>Current Products and Pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiopharma</td>
<td>✔ Focused on high value niche products with diagnostic and/or therapeutic uses</td>
</tr>
<tr>
<td></td>
<td>✔ Received 505(b)(2) approvals for RUBY-FILL® and Drax Exametazime™</td>
</tr>
<tr>
<td></td>
<td>✔ Planning to file NDA for I-131 mIBG and 505(b)(2) for 7 other products</td>
</tr>
<tr>
<td>Allergy Therapy Products</td>
<td>✔ Filed venom and allergenic extracts for use in animals</td>
</tr>
<tr>
<td>APIs</td>
<td>✔ Strong pipeline in APIs segment; 97 DMF filings in the US</td>
</tr>
<tr>
<td>Solid Dosage Formulations</td>
<td>✔ Strong pipeline in Generics segment; 98 ANDA filings in the US, of which 35 are pending approval</td>
</tr>
</tbody>
</table>

Solid Dosage Formulations (# of products)^(1)

- US: 98
  - Approved: 63
  - Pending: 24
- Canada: 35
  - Approved: 6
  - Pending: 28
- Europe: 39
- RoW: 41

Sterile Injectables (# of products)^(1)

- US: 16
  - Approved: 13
  - Pending: 0
- Canada: 17
- Europe: 4
- RoW: 10

Note: All data is as of March 31, 2020
(1) Product filings across geographies may pertain to overlapping products in the pipeline
Global Competitive Edge due to Integrated and Efficient Manufacturing Operations

Integrated Operations...

- Radiopharmacies
  - Provides direct access to hospital networks - ability to deliver c.3m+ patient doses annually to c.1,700 customers\(^{(1)}\)

- Radiopharmaceuticals and Allergy
  - All cold-kits for radiopharmaceuticals and certain allergy products are manufactured at CMO facility

- CMO

- Formulations
  - APIs from the manufacturing facility are used for solid dosage formulations (15% of APIs used is in-house)

\(^{(1)}\) Pursuant to acquisition of radiopharmacy business of Triad in FY18.
Demonstrated Financial Track Record with Strong Revenue Growth...

- Revenue from operations increased at a CAGR of 14% between FY18-FY20
- EBITDA increased at a CAGR of 18% during FY18-FY20
- Specialty Pharmaceuticals business contribution to revenue increased from 50% in FY18 to 53% in FY20
- Focused on leveraging free cash flows generated from our operations to reduce leverage and also invest in growth
- PAT increased at a CAGR of 37% during FY18-FY20. PAT margin improved to 11.4% in FY20 from 7.9% in FY18

Note: All financials include contribution from radiopharmacies (Triad Isotopes) from the period starting September 1, 2017

(1) Please note that the overall EBITDA includes unallocated depreciation and unallocated corporate expenses, which are not included in Segment EBITDA.
(2) Calculate as % of revenue from operations
...and a robust balance sheet

### Total Assets

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Assets (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY18</td>
<td>925</td>
</tr>
<tr>
<td>FY19</td>
<td>1,053</td>
</tr>
<tr>
<td>FY20</td>
<td>1,076</td>
</tr>
</tbody>
</table>

### Networth

<table>
<thead>
<tr>
<th>Year</th>
<th>Networth (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY18</td>
<td>384</td>
</tr>
<tr>
<td>FY19</td>
<td>408</td>
</tr>
<tr>
<td>FY20</td>
<td>430</td>
</tr>
</tbody>
</table>

### Cash Flows from Operations<sup>(1)</sup>

<table>
<thead>
<tr>
<th>Year</th>
<th>Cash Flows from Operations (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY18</td>
<td>116</td>
</tr>
<tr>
<td>FY19</td>
<td>128</td>
</tr>
<tr>
<td>FY20</td>
<td>167</td>
</tr>
</tbody>
</table>

### Capital Expenditures

<table>
<thead>
<tr>
<th>Year</th>
<th>Capital Expenditures (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY18</td>
<td>51</td>
</tr>
<tr>
<td>FY19</td>
<td>48</td>
</tr>
<tr>
<td>FY20</td>
<td>48</td>
</tr>
</tbody>
</table>

### Leverage

- **Consistent reduction in Net Debt to EBITDA**
  - ND/EBITDA: 2.5x, 2.2x, 1.4x

### Working Capital<sup>(2)</sup>

<table>
<thead>
<tr>
<th>Year</th>
<th>Working Capital (US$m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY18</td>
<td>142</td>
</tr>
<tr>
<td>FY19</td>
<td>216</td>
</tr>
<tr>
<td>FY20</td>
<td>147</td>
</tr>
</tbody>
</table>

Note: All financials include contribution from radiopharmacies (Triad Isotopes) from the period starting September 1, 2017.

<sup>(1)</sup> Net cash generated from operating activities

<sup>(2)</sup> Working Capital = Current Assets excluding Cash and Cash Equivalents – Current Liabilities excluding Loans and Borrowings

Capex as a % of Sales: 8.3%, 6.3%, 6.0%

Working Capital Days of Sales: 84, 104, 67<sup>(1)</sup>
Strong Acquisitions and Integration Capabilities with a Proven Track Record

1. Nanjangud Facility
   - First acquisition in the APIs space – The Group’s APIs are produced at this facility

2. Expansion of solid dosage formulations capabilities in North America

3. HollisterStier
   - Gained a strong foothold in two new business lines – Contract manufacturing of sterile injectables and allergy therapy products, with existing ‘HollisterStier’ brand

4. DRAXIS (radiopharmaceuticals & CMO business)
   - Entered the radiopharmaceuticals business

5. CADISTA
   - Acquired balance minority stake to consolidate ownership

6. Triad Isotopes
   - Vertical integration of the radiopharmaceuticals business – network of over 50 radiopharmacies across 22 states in the US

- Successful acquisitions leading to diversification and entry into differentiated niche businesses
- Capabilities built through successful integration of past acquisitions
- Positioned for future growth
- Specialist in-house strategy team to identify and evaluate opportunities
Highly Qualified, Experienced and Dedicated Board and Management Team

### Promoters

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Experience/Qualifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shyam S. Bhartia</td>
<td>Chairman and Managing Director</td>
<td>39 years of experience in the pharmaceuticals and specialty chemicals, food, oil and gas and aerospace, A fellow member of the Institute of Cost Accountants of India</td>
</tr>
<tr>
<td>Hari S. Bhartia</td>
<td>Co-Chairman &amp; Non-Executive Director</td>
<td>Over 33 years of experience in the pharmaceuticals and specialty chemicals, food, oil and gas, and aerospace, B.Tech (Chemical Engineering, Indian Institute of Technology, Delhi)</td>
</tr>
</tbody>
</table>

### Independent Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Experience/Qualifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suresh Kumar</td>
<td>Lead Independent Non-Executive Director</td>
<td>Has been a Member of Sanofi’s Executive Committee and spearheaded exports and FDI initiatives in the Obama Administration, Holds an Economics degree and Masters in Management</td>
</tr>
<tr>
<td>Fang Ai Lian</td>
<td>Independent Non-Executive Director</td>
<td>Worked with Ernst &amp; Young (EY) for over 30 years and retired as Chairman of EY, Singapore in 2008, A fellow of the Institute of Chartered Accountants in England and Wales and a fellow of the Institute of Singapore Chartered Accountants</td>
</tr>
<tr>
<td>Arun Duggal</td>
<td>Independent Non-Executive Director</td>
<td>Long and distinguished career of 26 years with Bank of America. Advised various companies, private equity firms and financial institutions on financial strategy, M&amp;A and capital raising, Holds bachelor’s degree in Mech. Engineering from IIT and post graduate Diploma in Business Admn. from IIM</td>
</tr>
<tr>
<td>Dr. Ashok Misra</td>
<td>Non-Executive Non-Independent Director</td>
<td>Rich experience in the field of Polymer Science and Engineering, B. Tech. in Chemical Engineering from IIT, Kanpur and M.S. in Chemical Engineering from Tufts University, Medford, MA, USA. Holds Doctorate Degree in Polymer Science &amp; Engineering by the University of Massachusetts, Amherst, USA.</td>
</tr>
</tbody>
</table>

### Senior Management

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Experience/Qualifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramod Yadav</td>
<td>Director and Chief Executive Officer</td>
<td>Over 30 years of industry experience, Holds a bachelor’s degree from the Institute of Chemical Technology and a Masters in Marketing Management from Jamnalal Bajaj Institute of Management, Mumbai</td>
</tr>
<tr>
<td>Mitchell Guss</td>
<td>Vice President (Legal)</td>
<td>Over 30 years of legal experience, A member of the New York State Bar and holds a Limited In House Corporate License in the State of Pennsylvania</td>
</tr>
</tbody>
</table>

+ Promoters continue to play an active role in driving the long term strategy for the business
+ Distinguished Board of Directors with an average of 30 years of industry experience
+ Senior management team has an average of 20 years of pharma industry experience
Agenda

- Jubilant Pharma
  - Key Highlights
  - Appendix
FY20 Highlights

Pharmaceuticals revenue at USD 803 Mn, increased 6% YoY led by growth in all three revenue segments with 5% growth in Specialty Pharma, 4% growth in CDMO and 9% growth in Generics

**Specialty Pharma**
- Revenue increased 5% YoY to USD 427 Mn
- Radiopharma revenue increased by 4% YoY led by higher volumes in key products with strong growth witnessed in Ruby-Fill®
- Received favorable ruling from U.S. International Trade Commission in Ruby-Fill®
- Allergy business’ revenue grew by 12% driven by higher volumes in venom and allergenic extracts and better prices

**CDMO**
- Revenue increased 4% YoY to USD 217 Mn
- CMO business grew by 13% YoY led by strong demand witnessed from key customers, which was reflected by higher volumes as compared to FY19
- Lower API revenue was due to lower volume in sartans as compared to previous year, which was partly mitigated by better prices.
- Lower volumes during the year was due to additional quality checks on all input raw materials to meet enhanced regulatory requirements. Plant shutdown in last week of March 2020 impacted sales as dispatches were scheduled during that week

**Generics**
- Revenue growth of 9% YoY was mainly due to better prices in some products

Pharmaceuticals EBITDA at USD 211 Mn up 10% YoY with a margin of 26.2% as compared to 25.2% in FY19

---

### FY19 vs FY20

<table>
<thead>
<tr>
<th>Particulars</th>
<th>FY19</th>
<th>FY20</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>761</td>
<td>803</td>
<td>6%</td>
</tr>
<tr>
<td>Specialty Pharma</td>
<td>405</td>
<td>427</td>
<td>5%</td>
</tr>
<tr>
<td>Radiopharma</td>
<td>353</td>
<td>369</td>
<td>4%</td>
</tr>
<tr>
<td>Allergy Therapy Products</td>
<td>52</td>
<td>58</td>
<td>12%</td>
</tr>
<tr>
<td>CDMO</td>
<td>209</td>
<td>217</td>
<td>4%</td>
</tr>
<tr>
<td>CMO</td>
<td>112</td>
<td>127</td>
<td>13%</td>
</tr>
<tr>
<td>Active Pharmaceuticals Ingredients</td>
<td>98</td>
<td>90</td>
<td>-8%</td>
</tr>
<tr>
<td>Generics</td>
<td>147</td>
<td>160</td>
<td>9%</td>
</tr>
<tr>
<td>Reported EBITDA</td>
<td>192</td>
<td>211</td>
<td>10%</td>
</tr>
<tr>
<td>Reported EBITDA Margin</td>
<td>25.2%</td>
<td>26.2%</td>
<td></td>
</tr>
</tbody>
</table>

---

1. All figures are in USD Mn unless otherwise stated
## Summary Income Statement

(US$m, unless stated)

<table>
<thead>
<tr>
<th></th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue from Operations</strong></td>
<td>619</td>
<td>761</td>
<td>803</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>151</td>
<td>192</td>
<td>211</td>
</tr>
<tr>
<td>Margin (%)</td>
<td>24.5%</td>
<td>25.2%</td>
<td>26.2%</td>
</tr>
<tr>
<td>Depreciation, amortization and impairment</td>
<td>(56)</td>
<td>(40)</td>
<td>(48)</td>
</tr>
<tr>
<td><strong>Result from operating activities (EBIT)</strong></td>
<td>96</td>
<td>152</td>
<td>163</td>
</tr>
<tr>
<td>Margin (%)</td>
<td>15.5%</td>
<td>20.0%</td>
<td>20.3%</td>
</tr>
<tr>
<td><strong>Finance Cost</strong></td>
<td>(12)</td>
<td>(12)</td>
<td>(25)</td>
</tr>
<tr>
<td><strong>Profit before tax</strong></td>
<td>73</td>
<td>100</td>
<td>138</td>
</tr>
<tr>
<td><strong>Income tax expense</strong></td>
<td>(24)</td>
<td>(42)</td>
<td>(46)</td>
</tr>
<tr>
<td><strong>PAT</strong></td>
<td>49</td>
<td>59</td>
<td>92</td>
</tr>
<tr>
<td>Margin (%)</td>
<td>7.9%</td>
<td>7.7%</td>
<td>11.4%</td>
</tr>
</tbody>
</table>

**Note:**
(1) Calculated as % of revenue from operations
## Summary Balance Sheet

<table>
<thead>
<tr>
<th>Assets</th>
<th>As at 31-Mar-18</th>
<th>As at 31-Mar-19</th>
<th>As at 31-Mar-20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>278</td>
<td>284</td>
<td>275</td>
</tr>
<tr>
<td>Goodwill</td>
<td>169</td>
<td>165</td>
<td>160</td>
</tr>
<tr>
<td>Other assets</td>
<td>200</td>
<td>186</td>
<td>204</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td>647</td>
<td>635</td>
<td>640</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories</td>
<td>112</td>
<td>124</td>
<td>147</td>
</tr>
<tr>
<td>Trade receivables</td>
<td>106</td>
<td>117</td>
<td>116</td>
</tr>
<tr>
<td>Other financial assets</td>
<td>9</td>
<td>59</td>
<td>10</td>
</tr>
<tr>
<td>Income tax assets</td>
<td>1</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>Other current assets</td>
<td>23</td>
<td>27</td>
<td>25</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>27</td>
<td>90</td>
<td>138</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>278</td>
<td>418</td>
<td>437</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>925</td>
<td>1053</td>
<td>1076</td>
</tr>
</tbody>
</table>

## Equity and liabilities

<table>
<thead>
<tr>
<th>Equity and liabilities</th>
<th>As at 31-Mar-18</th>
<th>As at 31-Mar-19</th>
<th>As at 31-Mar-20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Equity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity share capital</td>
<td>327</td>
<td>327</td>
<td>327</td>
</tr>
<tr>
<td>Foreign currency translation reserve</td>
<td>(22)</td>
<td>(49)</td>
<td>(86)</td>
</tr>
<tr>
<td>Other components of equity</td>
<td>80</td>
<td>130</td>
<td>189</td>
</tr>
<tr>
<td><strong>Total equity attributable to owners of the Company</strong></td>
<td>384</td>
<td>408</td>
<td>430</td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loans and borrowings</td>
<td>394</td>
<td>496</td>
<td>397</td>
</tr>
<tr>
<td>Other non-current liabilities</td>
<td>24</td>
<td>28</td>
<td>54</td>
</tr>
<tr>
<td><strong>Total non-current liabilities</strong></td>
<td>418</td>
<td>524</td>
<td>451</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loans and borrowings</td>
<td>14</td>
<td>10</td>
<td>44</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>17</td>
<td>19</td>
<td>26</td>
</tr>
<tr>
<td>Trade payables</td>
<td>62</td>
<td>66</td>
<td>69</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>29</td>
<td>26</td>
<td>57</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>123</td>
<td>121</td>
<td>196</td>
</tr>
<tr>
<td><strong>Total equity and liabilities</strong></td>
<td>925</td>
<td>1053</td>
<td>1076</td>
</tr>
</tbody>
</table>
## Summary Cash Flow Statement

<table>
<thead>
<tr>
<th></th>
<th>FY18</th>
<th>FY19</th>
<th>FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating cash flow before working capital changes</td>
<td>151</td>
<td>190</td>
<td>211</td>
</tr>
<tr>
<td>Cash generated from operations</td>
<td>144</td>
<td>169</td>
<td>198</td>
</tr>
<tr>
<td>Net cash generated from operating activities</td>
<td>116</td>
<td>128</td>
<td>167</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>(67)</td>
<td>(94)</td>
<td>7</td>
</tr>
<tr>
<td>Net cash used in financing activities</td>
<td>(70)</td>
<td>31</td>
<td>(123)</td>
</tr>
<tr>
<td>Cash and cash equivalents at the end of the year/period</td>
<td>27</td>
<td>90</td>
<td>138</td>
</tr>
</tbody>
</table>
Q1’FY21 Highlights

<table>
<thead>
<tr>
<th></th>
<th>Q1’FY20</th>
<th>Q1’FY21</th>
<th>Change (% YoY)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speciality Pharma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharma</td>
<td>104</td>
<td>70</td>
<td>-33%</td>
</tr>
<tr>
<td>Allergy Therapy Products</td>
<td>13</td>
<td>10</td>
<td>-26%</td>
</tr>
<tr>
<td>CDMO</td>
<td>50</td>
<td>37</td>
<td>-26%</td>
</tr>
<tr>
<td>CMO</td>
<td>32</td>
<td>34</td>
<td>5%</td>
</tr>
<tr>
<td>Active Pharmaceutical Ingredients</td>
<td>18</td>
<td>3</td>
<td>-82%</td>
</tr>
<tr>
<td>Generics</td>
<td>36</td>
<td>37</td>
<td>4%</td>
</tr>
<tr>
<td><strong>Reported EBITDA</strong></td>
<td>46</td>
<td>22</td>
<td>-52%</td>
</tr>
<tr>
<td><strong>Reported EBITDA margin</strong></td>
<td>24.0%</td>
<td>15.1%</td>
<td></td>
</tr>
</tbody>
</table>

Pharmaceuticals revenue was at USD 145 Mn in Q1’FY21

**Specialty Pharmaceuticals**
- Radiopharma business revenue was impacted by decline in elective procedures due to COVID-19. Radiopharma sales have normalized to around 90% of pre-COVID levels
  - Ruby-Fill commercial launch in Europe planned in FY21
- Allergy business volumes were affected by decline in patient visits due to COVID-19. Volumes have normalized to 100% of pre-COVID levels

**CDMO**
- CMO business’ revenue grew based on strong demand from customers
- Initiatives taken to increase total capacity by over 30% with annual potential revenues of around USD 30 Mn
  - Increased shifts to 24x7 on Line 2 from Q3’FY19 and on line 1 from Q3’FY20 onwards
  - Commissioning of the new Lyo equipment completed during Q1’FY21
- Entered into four separate clinical and commercial supply agreements for COVID-19 treatment and vaccine candidates. Strong outlook due to robust order book and new business sign-ups
- In API, revenue decreased due to the two month temporary suspension of operations at Nanjangud plant due to COVID-19. Plant resumed production in June 2020 and is witnessing strong demand

**Generics**
- Revenue growth during the quarter was led by strong performance in the US market driven by certain key products

1. All figures are in USD Mn unless otherwise stated
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIT</td>
<td>Allergen Immunotherapy</td>
</tr>
<tr>
<td>ANDA</td>
<td>Abbreviated New Drug Application</td>
</tr>
<tr>
<td>API</td>
<td>Active Pharmaceutical Ingredient</td>
</tr>
<tr>
<td>ATP</td>
<td>Allergy Therapy Business</td>
</tr>
<tr>
<td>CDMO</td>
<td>Contract Development and Manufacturing</td>
</tr>
<tr>
<td>CMO</td>
<td>Contract Manufacturing Operations</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>CVS</td>
<td>Cardio-Vascular System</td>
</tr>
<tr>
<td>DMF</td>
<td>Drug Master File</td>
</tr>
<tr>
<td>DTPA</td>
<td>Diethylene Triamine Penta Acetic Acid</td>
</tr>
<tr>
<td>GPO</td>
<td>Group Purchasing Organization</td>
</tr>
<tr>
<td>I-131</td>
<td>Iodine-131</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>MAA</td>
<td>Macro Aggregates of Albumin</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare Products Regulatory Agency (United Kingdom)</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>PET</td>
<td>Position Emission Tomography</td>
</tr>
<tr>
<td>PMDA</td>
<td>Pharmaceuticals and Medical Devices Agency (Japan)</td>
</tr>
<tr>
<td>USDA</td>
<td>The United States Department of Agriculture</td>
</tr>
<tr>
<td>USFDA</td>
<td>United States Food and Drug Administration</td>
</tr>
</tbody>
</table>